← All trials
NCT04759534
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2020
- Primary completion
- Oct 30, 2021
- Completion date
- Nov 30, 2021
- First posted
- Feb 18, 2021
- Last posted
- Aug 25, 2021
- Enrollment
- 20
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shenzhen UniversityLead sponsor
- Shenzhen UniversityStudy chair
- Innovent Biologics (Suzhou) Co. Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.